Cargando…

Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

BACKGROUND: The aim of this substudy of the ghrelin treatment, multicenter, randomized, double-blind, placebo-controlled trial was to investigate the effects of ghrelin administration on exercise capacity and the underlying mechanisms in underweight patients with chronic obstructive pulmonary diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Miki, Keisuke, Maekura, Ryoji, Nagaya, Noritoshi, Kitada, Seigo, Miki, Mari, Yoshimura, Kenji, Tateishi, Yoshitaka, Motone, Masaharu, Hiraga, Toru, Mori, Masahide, Kangawa, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683541/
https://www.ncbi.nlm.nih.gov/pubmed/23758800
http://dx.doi.org/10.1186/1471-2466-13-37
Descripción
Sumario:BACKGROUND: The aim of this substudy of the ghrelin treatment, multicenter, randomized, double-blind, placebo-controlled trial was to investigate the effects of ghrelin administration on exercise capacity and the underlying mechanisms in underweight patients with chronic obstructive pulmonary disease (COPD) using cardiopulmonary exercise testing. METHODS: Twenty underweight COPD patients were randomized to pulmonary rehabilitation with intravenous ghrelin (2 μg/kg, n = 10) or placebo (n = 10) twice daily for 3 weeks in a double-blind fashion. The primary outcome was changes in peak oxygen uptake [Formula: see text]. Secondary outcomes included changes in exertional cardio-respiratory functions: O(2)-pulse, physiologic dead space/tidal volume-ratio (V(D)/V(T)), ventilatory equivalent for oxygen [Formula: see text] , and ventilatory equivalent for carbon dioxide [Formula: see text]. RESULTS: With incremental exercise, at peak exercise, there was a significant difference in the mean difference (ghrelin minus placebo), i.e., treatment effect in: i) peak [Formula: see text] (1.2 mL/kg/min, 95% CI: 0.2-2.3 mL/kg/min, between-group p = 0.025); ii) [Formula: see text] (-4.2, 95% CI: -7.9 to -0.5, between-group p = 0.030); iii) [Formula: see text] (-4.1, 95% CI: -8.2 to -0.1, between-group p = 0.045); iv) V(D)/V(T) (-0.04, 95% CI: -0.08 to -0.00, between-group p = 0.041); and v) O(2)-pulse (0.7 mL/beat, 95% CI: 0.3 to 1.2 mL/beat, between-group p = 0.003). Additionally, repeated-measures analysis of variance (ANOVA) indicated a significant time-course effect of ghrelin versus placebo in the peak [Formula: see text] (p = 0.025). CONCLUSION: Ghrelin administration was associated with improved exertional capacity and improvements in ventilatory-cardiac parameters. TRIAL REGISTRATION: UMIN (University Hospital Medical Information Network in Japan) C000000061